Inflammatory airway diseases with an inflammatory cytokine profile similar to that of TB, which is driven specifically by IL-17A oversecretion, appear to be resolved with the use of a p110δ inhibitor such as Leniolisib. Here, IL17A is linked to tuberculosis.